Active Ingredient(s): Sotorasib
FDA Approved: * May 28, 2021
Pharm Company: * AMGEN INC
Category: Cancer

Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer (NSCLC).[1][2] It targets a specific mutation, G12C, in the protein KRAS which is responsible for various forms of cancer.[3][4] The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.[1][2] Sotorasib is an inhibitor... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lumakras 120 mg Oral Tablet, Coated
NDC: 55513-488
Amgen Inc
Lumakras 320 mg Oral Tablet, Coated
NDC: 55513-504
Amgen Inc